AASLD 2011: BI 201335 Performs Well with Standard Therapy

Once-daily BI 201335 added to pegylated interferon/ribavirin for 24 weeks produced consistently high SVR rates across difficult-to-treat chronic hepatitis C patient subgroups, according to findings from the SILEN-C1 study presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco. A follow-up study showed that rapid responders did equally well with 12 or 24 weeks of treatment.

Read more:

AASLD 2011: Deaths Due to Hepatitis C Now Exceed HIV Deaths

Deaths related to hepatitis C virus (HCV) and its complications have exceeded deaths due to HIV/AIDS since 2007, according to an analysis by Centers for Disease Control and Prevention (CDC) researchers presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco.

Read more:

AASLD 2011: HCV Direct-Acting Antivirals Boost Interferon Response Rates

Several studies at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco showed that adding experimental direct-acting antiviral (DAA) agents to pegylated interferon plus ribavirin increases virological response rates for people with chronic hepatitis C.

BI 201335 Performs Well with Standard Therapy

TMC435 + Pegylated Interferon/Ribavirin

PSI-7977 + Pegylated Interferon/Ribavirin

12-week Daclatasvir + Pegylated Interferon/Ribavirin

Danoprevir + Pegylated Interferon/Ribavirin

AASLD 2011: Do Hepatitis C Patients with Cirrhosis Benefit from Adding Telaprevir?

Adding telaprevir to pegylated interferon/ribavirin increased the likelihood of a cure for genotype 1 chronic hepatitis C patients with liver cirrhosis in the REALIZE trial, according to data presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco.

Read more: